RITUXAN (also known as Rituximab)
Rituxan is an antibody directed against CD20 on B lymphocytes and targets problematic cells for destruction.
- Active, moderate-to-severe rheumatoid arthritis in conjunction with Methotrexate
- Granulomatosis with Polyangiitis
- Microscopic Polyangiitis
Patients with active infection should not be started on Rituxan.
Rituxan is typically administered as an infusion. For patients with Rheumatoid Arthritis, Rituxan is often initiated and repeated after 2 weeks and then maintained every 24 weeks thereafter.